论文部分内容阅读
探讨前列腺特异性抗原（PSA）在前列腺癌诊治中的变化及意义。采用双抗体放射免疫分析法测定78例前列腺良、恶性病变患者血清PSA含量，观察31例前列腺癌患者内分泌治疗后PSA变化。结果：前列腺癌组与前列腺增生症组比较，血清PSA差异有极显著性意义（P＜0．01）。前列腺癌临床各期两两比较，血清PSA有极显著性差异（P＜0．01）或显著性差异（P＜0．05）。各组分化程度不同的前列腺癌相比较，血清PSA均无显著性差异（P＞0．05）。前列腺癌患者中核素骨扫描提示癌骨转移与未提示骨转移两组血清PSA比较有极显著性差异（P＜0．01）。血清PSA明显异常可以预测骨转移的概率．血清PSA的动态变化与临床病情演变基本一致。结论：采用双抗体放射免疫分析法进行血清PSA测定在前列腺癌诊治中是一个较敏感而有价值的指标。血清PSA检测与核素骨扫描联合应用对于前列腺癌的诊断以及了解疾病演进会有很大的帮助。
To investigate the changes and clinical significance of prostate-specific antigen (PSA) in the diagnosis and treatment of prostate cancer. Serum PSA levels in 78 patients with benign and malignant prostatic lesions were determined by double antibody radioimmunoassay and the PSA changes after endocrine therapy in 31 patients with prostate cancer were observed. Results: Compared with benign prostatic hyperplasia (BPH) group, the difference of serum PSA was significant (P <0.01). There were significant differences (P <0.01) or significant differences (P <0.05) in the serum PSA between the two groups in each stage of prostate cancer. There was no significant difference in serum PSA between different groups of different degree of differentiation of prostate cancer (P> 0.05). Radionuclide bone scan in patients with prostate cancer suggests that there is a very significant difference in serum PSA between the two groups (P <0.01). Serum PSA abnormalities can predict the probability of bone metastases. Serum PSA dynamic changes and clinical evolution of the basic conditions. Conclusion: Serum PSA assay using double antibody radioimmunoassay is a sensitive and valuable indicator in the diagnosis and treatment of prostate cancer. Serum PSA test and radionuclide bone scan in combination for the diagnosis of prostate cancer and understanding of the evolution of the disease will be of great help.